Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer

Ge,Xiao‑Chuan; Wu,Fan; Li,Wei‑Tao; Zhu,Xuan‑Jin; Liu,Jian‑Wei; Wang,Bai‑Lin

doi:10.3892/ol.2017.5984

Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer

Authors:
- Xiao‑Chuan Ge
- Fan Wu
- Wei‑Tao Li
- Xuan‑Jin Zhu
- Jian‑Wei Liu
- Bai‑Lin Wang
View Affiliations

Affiliations: Department of General Surgery, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou, Guangdong 510220, P.R. China
Published online on: April 4, 2017 https://doi.org/10.3892/ol.2017.5984
Pages: 4341-4348

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

WEE1 is a serine/threonine protein kinase that inactivates cell division cycle 2 and is therefore a critical cell cycle regulator. Increased WEE1 expression has been observed in numerous types of human malignancies, including hepatocellular carcinoma and melanoma. WEE1 inhibition also results in evident anti‑tumor effects in several human tumor cells including colon cancer cells, suggesting WEE1 as a potential therapeutic target for the treatment of cancer. However, the expression pattern of WEE1 in colorectal cancer (CRC) remains unclear. In the present study, WEE1 mRNA expression in 43 cases of CRC tissues matched with adjacent normal tissues was determined by reverse‑transcription quantitative polymerase chain reaction. The results demonstrated that WEE1 mRNA expression was significantly increased in CRC tissues and that this upregulation correlated significantly with hepatic metastasis, distant metastasis and high tumor node metastasis (TNM) stage of CRC. Additionally, WEE1 protein in 102 CRC tissue samples was detected by immunohistochemistry, and positive staining of WEE1 was identified in more than half of patients with CRC. WEE1 staining scores were also observed to be associated with distant metastasis and high TNM stage of CRC. In addition, patients with CRC with high WEE1 staining score (2+ or 3+) exhibited either poorer overall survival or poorer disease‑free survival compared with those with low WEE1 staining score (0 or 1+). The multivariable Cox model also identified a high WEE1 staining score as well as high TNM stage to be independent prognostic factors for CRC. In conclusion, WEE1 upregulation is associated with a high degree of malignancy and poor prognosis of CRC, suggesting WEE1 as a potential prognostic biomarker for CRC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, et al: Asia Pacific consensus recommendations for colorectal cancer screening. Gut. 57:1166–1176. 2008. View Article : Google Scholar : PubMed/NCBI
3	Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T; Japan Cancer Surveillance Research Group, : Cancer incidence and incidence rates in Japan in 2006: Based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 42:139–147. 2012. View Article : Google Scholar : PubMed/NCBI
4	Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, Van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature. 327:293–297. 1987. View Article : Google Scholar : PubMed/NCBI
5	Baker SJ, Markowitz S, Fearon ER, Willson JK and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249:912–925. 1990. View Article : Google Scholar : PubMed/NCBI
6	Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya J, Baba S and Hedge P: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 253:665–669. 1991. View Article : Google Scholar : PubMed/NCBI
7	Wu F, Shirahata A, Sakuraba K, Kitamura Y, Goto T, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y and Hibi K: Downregulation of Mus81 as a novel prognostic biomarker for patients with colorectal carcinoma. Cancer Sci. 102:472–477. 2011. View Article : Google Scholar : PubMed/NCBI
8	Wu F, Shirahata A, Sakuraba K, Kitamura Y, Goto T, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y and Hibi K: Down-regulation of EGFL8: A novel biomarker for advanced gastric cancer. Anticancer Res. 31:3377–3380. 2011.PubMed/NCBI
9	Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 9:489–499. 2009. View Article : Google Scholar : PubMed/NCBI
10	Thuriaux P, Nurse P and Carter B: Mutants altered in the control co-ordinating cell division with cell growth in the fission yeast Schizosaccharomyces pombe. Mol Gen Genet. 161:215–220. 1978.PubMed/NCBI
11	Perry JA and Kornbluth S: Cdc25 and Wee1: Analogous opposites? Cell Div. 2:122007. View Article : Google Scholar : PubMed/NCBI
12	Mueller PR, Coleman TR, Kumagai A and Dunphy WG: Myt1: A membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science. 270:86–90. 1995. View Article : Google Scholar : PubMed/NCBI
13	Parker LL and Piwnica-Worms H: Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science. 257:1955–1957. 1992. View Article : Google Scholar : PubMed/NCBI
14	Watanabe N, Broome M and Hunter T: Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EBMO J. 14:1878–1891. 1995.
15	Kawabe T: G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. 3:513–519. 2004.PubMed/NCBI
16	Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H, Watanabe S, et al: Cyclins and cyclin-dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
17	Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A and Flørenes VA: High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: Potential for targeted therapy. PLoS One. 7:e382542012. View Article : Google Scholar : PubMed/NCBI
18	Magnussen GI, Hellesylt E, Nesland JM, Trope CG, Flørenes VA and Holm R: High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer. 13:2882013. View Article : Google Scholar : PubMed/NCBI
19	Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B and Flørenes VA: Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol Oncol. 135:118–124. 2014. View Article : Google Scholar : PubMed/NCBI
20	Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ, et al: In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 18:244–257. 2010. View Article : Google Scholar : PubMed/NCBI
21	Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, Mein CA, Natrajan R, Savage K, Tamber N, et al: Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One. 4:e51202009. View Article : Google Scholar : PubMed/NCBI
22	Murrow LM, Garimella SV, Jones TL, Caplen NJ and Lipkowitz S: Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat. 122:347–357. 2010. View Article : Google Scholar : PubMed/NCBI
23	Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM and Porter CC: AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget. 6:28001–28010. 2015. View Article : Google Scholar : PubMed/NCBI
24	Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, et al: MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther. 9:514–522. 2010. View Article : Google Scholar : PubMed/NCBI
25	Weisberg E, Nonami A, Chen Z, Liu F, Zhang J, Sattler M, Nelson E, Cowens K, Christie AL, Mitsiades C, Wong KK, et al: Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia. 29:27–37. 2015. View Article : Google Scholar : PubMed/NCBI
26	Backert S, Gelos M, Kobalz U, Hanski ML, Böhm C, Mann B, Lövin N, Gratchev A, Mansmann U, Moyer MP, et al: Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int J Cancer. 82:868–874. 1999. View Article : Google Scholar : PubMed/NCBI
27	Wu F, Liu SY, Tao YM, Ou DP, Fang F and Yang LY: Decreased expression of methyl methansulfonate and ultraviolet-sensitive gene clone 81 (Mus81) is correlated with a poor prognosis in patients with hepatocellular carcinoma. Cancer. 112:2002–2010. 2008. View Article : Google Scholar : PubMed/NCBI
28	Huisman SA, Oklejewicz M, Ahmadi AR, Tamanini F, Ijzermans JN, van der Horst GT and de Bruin RW: Colorectal liver metastases with a disrupted circadian rhythm phase shift the peripheral clock in liver and kidney. Int J Cancer. 136:1024–1032. 2015. View Article : Google Scholar : PubMed/NCBI
29	Karantanos T, Theodoropoulos G, Pektasides D and Gazouli M: Clock genes: Their role in colorectal cancer. World J Gastroenterol. 20:1986–1992. 2014. View Article : Google Scholar : PubMed/NCBI
30	Zlobec I and Lugli A: Prognostic and predictive factors in colorectal cancer. J Clin Pathol. 61:561–569. 2008.PubMed/NCBI